11 / 28
Notes:
Volume 6, Issue 4 (Suppl)
Clin Pharmacol Biopharm, an open access journal
ISSN: 2167-065X
Page 27
Euro Biopharma & Ethnopharmacology 2017
November 09-11, 2017
&
6
th
International Conference and Exhibition on
November 09-11, 2017 Vienna, Austria
4
th
EUROPEAN BIOPHARMA CONGRESS
PHARMACOLOGY AND ETHNOPHARMACOLOGY
Joint Event
Isolation and structure elucidation of new cytotoxic polypeptide from bee venom
Hesham R El-Seedi
1
, Aida A Abd El-Wahed
1,2
, Robert Burmana
1
and
Ulf Göransson
1
1
University of Malaya, Malaysia
2
Plant Protection Research Institute - Agricultural Research Centre, Egypt
H
oneybee is an important economic insect, which have vital role in the pollination for crops and wild flowers. In addition to
ecological importance, honeybee supplies with various products, including bee venom (BV). This venom has been used in
traditional medicine for thousands of years and there is an increasing interest in their applications in modern medicine. BV has
diverse biological activities as anticancer, antimicrobial, anti-inflammatory, antiviral and hepatoprotective. Today there is an urgent
call to find anticancer agents from the natural products with less ecological damage and minimum health and environmental hazards.
Our main aim is to identify and characterize the bioactive peptides from bee venom. These peptides have been poorly characterized,
partly because they are generally present in trace quantities. Isolated active peptides from the bee venom have been identified using
techniques including High Performance Liquid Chromatography (HPLC), Mass Spectrometry (MS, LC/MS, MS /MS), Amino Acid
Analysis (AAA) and 2D-Nuclear Magnetic Resonance Spectroscopy (2D-NMR). Polar fractionation prior to screening of anticancer
has been done. The bioassay-guided isolation for bee venom leads to isolation of four peptides melittin, apamin, MCD and secapin.
Melittin showed cytotoxic activity on three cancer cell lines: lymphoma cells U-937GTB, myeloma cells RPMI 8226/s, leukaemia
cells CCRF-CEM and two drug-resistant sub-lines (PRMI 8226/Dox40 and CEM/VM-1), with IC50 values of 1.3, 1.1, 1.4, 1.7, 2 µM,
respectively.
hesham.el-seedi@fkog.uu.seHesham R El-Seedi et al., Clin Pharmacol Biopharm 2017, 6:4(Suppl)
DOI: 10.4172/2167-065X-C1-025